1. Japan Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
Daicel Corporation

Daicel Corporation

7.95
EUR
-0.05
(-0.62%)
Nov 05Next Earn
Daicel Corporation
HAN:9DC
(Hannover Stock Exchange)

Recent

price

7.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
994.01
967.36
1,019.28
1,177.02
1,263.11
1,283.54
1,269.43
1,346.74
1,387.69
1,284.52
1,301.27
1,559.19
1,836.54
2,023.29
2,150.77
2,206.35
- -
Revenue per Share
47.22
33.46
43.7
64.98
88.95
115.02
124.61
107.81
105.38
15.49
65.18
104.14
138.87
202.43
181.44
38.75
- -
Basic EPS, GAAP
117.13
46.98
52.35
47.65
79.08
84.36
138.91
97.32
44.61
33.85
69.7
-14.92
-85.6
27.27
77.24
-0.68
- -
Free Cash Flow per Basic Share
10
11.01
10
13.01
17
25.98
26.07
33.2
32.19
32.39
34.44
32.14
36.36
46.62
55.63
60.57
- -
Dividend per Share
596.06
618.98
685.11
764.51
922.71
966.35
1,067.63
1,136.32
1,198.77
1,166.55
789.33
919.88
1,033.52
1,303.2
1,357.77
1,392.35
1,392.35
Book Value per Share
588.19
612.17
646.42
725.73
885.04
933.86
1,039.82
1,110.96
1,160.19
1,123.51
754.13
885.84
994.34
1,264.14
1,317.63
1,348.96
1,348.96
Tangible Book Value per Share
356
353
352
352
351
350
347
344
335
321
302
300
293
276
273
263
263
Basic Weighted Avg Shares
353,684
341,942
358,513
413,786
443,775
449,878
440,061
462,956
464,859
412,826
393,568
467,937
538,026
558,056
586,531
579,629
- -
Sales/Revenue/Turnover
9.25
5.97
7.31
9.16
11.56
14.3
14.61
12.73
11.01
7.18
8.06
10.83
8.83
11.18
10.4
7.26
- -
Operating Margin (%)
33,528
28,848
25,422
25,091
25,633
25,969
30,836
32,956
31,050
30,119
27,404
28,195
31,575
33,703
41,373
43,343
- -
Depreciation Expense
16,802
11,827
15,372
22,843
31,252
40,313
43,198
37,062
35,301
4,978
19,713
31,254
40,682
55,834
49,480
10,180
- -
Net Income, GAAP
22.93
29.75
29.63
36.3
31.82
26.67
22.13
24.93
21.97
31.31
32.1
30.74
24.24
25.63
22.93
56.26
- -
Effective Tax Rate (%)
4.75
3.46
4.29
5.52
7.04
8.96
9.82
8.01
7.59
1.21
5.01
6.68
7.56
10.01
8.44
1.76
- -
Profit Margin (%)
107,163
95,342
118,974
145,152
167,216
174,161
197,889
231,033
228,529
191,814
199,958
206,349
185,771
200,677
185,273
205,583
205,583
Working Capital
71,606
47,730
66,768
71,630
64,896
58,709
59,983
75,884
76,043
72,200
255,571
236,029
208,823
214,741
208,021
239,984
239,984
LT Debt
235,336
234,710
262,898
295,804
356,176
368,720
399,428
413,540
423,242
392,582
245,000
279,542
310,433
375,407
375,035
370,377
370,377
Total Equity
7.38
4.4
5.36
6.23
8.13
10.48
10.81
8.88
7.61
4.01
4.3
6.49
6
7.06
6.97
2.73
- -
Return on Invested Capital (%)
3.58
3.3
4.06
5.34
6.47
7.9
8.12
6.21
5.69
-0.13
3.58
5.85
6.87
8.65
7.51
1.55
- -
Return on Capital (%)
8.04
5.5
6.7
8.97
10.54
12.19
12.22
9.82
9.07
1.32
6.57
12.26
14.34
17.06
13.76
2.85
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
ST Debt
- -
58,984
64,267
LT Borrowings
- -
228,864
239,984
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
265
265
255
Market Capitalization
- -
- -
- -

Working Capital

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
Total Current Assets
- -
390,725
403,166
Cash, Cash Equivalents & STI
- -
64,684
68,811
Accounts Receivable, Net
- -
102,839
117,307
Inventories
- -
185,965
174,515
Total Current Liabilities
- -
198,854
197,583
Payables & Accruals
- -
- -
- -
ST Debt
- -
58,984
64,267
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.41%
8.95%
-1.24%
Free Cash Flow
33.15%
57.59%
-100.85%
Net Income, GAAP
23.35%
7.03%
-79.43%
Sales/Revenue/Turnover
2.91%
8.3%
-1.18%
Total Cash Common Dividend
6.32%
9.33%
4.89%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
130,802
140,202
143,272
143,780
558,056
2025
- -
- -
- -
- -
586,531
2026
- -
- -
- -
- -
579,629

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
52.46
51.67
51.28
41.96
202.43
2025
- -
- -
- -
- -
181.44
2026
- -
- -
- -
- -
38.75

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
46.62
2025
- -
- -
- -
- -
55.63
2026
- -
- -
- -
- -
60.57
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
PI Industries Limited (NSE:PIIND)
Business
Daicel Corporation manufactures and sells organic chemicals, engineering plastics, functional materials, and safety devices. The company produces acetic acid and derivatives, cellulose acetate products including acetate tow, alicyclic epoxy compounds, caprolactone derivatives, performance films, polymers and solvents for photoresists and electronic materials, optical lenses, polyacetal (POM), polybutylene terephthalite (PBT), polyphenylene sulfide (PPS), liquid crystal polymer (LCP), and cyclic olefin copolymer (COC); it also offers AS resin, acetate plastics, water-soluble polymers, barrier films for packaging, ABS resins, polymer alloys, plastic compounds, molded containers, reverse osmosis and ultrafiltration membranes for water treatment, chiral chromatography columns and separation services, pharma standards and reagents, bioprocess purification systems, purification membrane modules, airbag inflators, pyro-fuses for electric vehicles and energy storage, and needle-free injectors such as Actranza Lab. Daicel operates in four primary segments comprising advanced materials & chemicals, engineered materials & solutions, life sciences, and safety systems; it serves industries including electronics, automotive, medical/healthcare, cosmetics, pharmaceuticals, environment, and food packaging with target customers ranging from manufacturers to healthcare providers. Founded in 1919 and headquartered in Osaka, Japan, with additional key offices in Tokyo and global subsidiaries across Asia, Europe, and the Americas including Daicel Miraizu Ltd., Novacel Co., Ltd., Daicel Pack Systems Ltd., Daicel Chiral Technologies, and Polyplastics Co., Ltd. Recent developments include PMDA approval in 2025 for Daicel Medical Ltd.'s gas-powered needle-free injector in Japan; partnerships with Mitsui Chemicals and Polyplastics for engineering plastic marketing operations, Nagase & Co. for digital transformation in mixing processes using Mixing Concierge software, and earlier collaborations with Samsung SDI on battery materials and Toyota on automotive applications; a group reorganization plan announced in 2025 involving a company split with Polyplastics potentially including name changes; additional acquisition of shares in Toyama Filter Tow Co., Ltd. to form a wholly owned subsidiary; launch of eco-friendly cosmetic texture improver BELLOCEA BS7 emphasizing biodegradability; treasury stock acquisitions and disposals for shareholder returns; and ongoing investments in R&D for production efficiency, market expansions in Asia, and sustainability initiatives like a new carbon pricing system and EcoVadis Gold Medal recognition.